Laura Sala

Dr. Laura Sala

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
FGFederica Guffanti
Federica Guffanti
IMIlaria Mengoli
Ilaria Mengoli
Francesca RicciFrancesca Ricci
Francesca Ricci
LPLudovica Perotti
Ludovica Perotti
ECElena Capellini
Elena Capellini
MCMichela Chiappa
Michela Chiappa
Platinum resistance represents an urgent medical need in the management of ovarian cancer. The activity of the combinations of onvansertib, an inhibitor of polo-like kinase 1, with gemcitabine or carboplatin was tested using patient-derived xenografts of high-grade serous ovarian carcinoma resistant to cisplatin (DDP). Two PDX models were selected from our xenobank: one with acquired resistance to DDP (#266R) and the other (#315) with intrinsic DDP resistance. Tumor-bearing mice were randomized to receive vehicle, single onvansertib, gemcitabine and carboplatin, and their combinations. Onvansertib/gemcitabine and onvansertib/carboplatin combinations were well tolerated. In the #266R model, single drug treatments were completely inactive, while the combinations of onvansertib/gemcitabine and onvansertib/carboplatin resulted in a significant increase in survival compared to controls and single drugs (p < 0.001 versus control, onvansertib, gemcitabine and carboplatin). Similar efficacy was observed in the s.c. #315 PDX model; indeed, onvansertib and carboplatin monotherapies were inactive, gemcitabine monotherapy was marginally active, while both combinations were highly active. The molecular mechanism underlying the efficacy of the combinations suggests a higher induction of DNA damage which seems plausible considering that, in both cases, gemcitabine and carboplatin, respectively, interfere with DNA metabolism and induce alkylation damage. The results suggest that the combinations of onvansertib/gemcitabine and onvansertib/carboplatin are safe and were shown to be of therapeutic value in the platinum-resistant setting of ovarian carcinoma, strongly supporting their clinical translatability.

29 January 2025 in Veterinary Pathology
Verified
Journal Article
Closed access
LBLuca Bertola
Luca Bertola
GPGiovanna Pepe
Giovanna Pepe
ADArianna Dolce
Arianna Dolce
CLCristina Lecchi
Cristina Lecchi
Elena BorroniElena Borroni
Elena Borroni
CRCamilla Recordati
Camilla Recordati
Acute pancreatitis (AP) is a life-threatening condition, with a higher mortality rate in men than women and in which estrogens might play a protective role. This study aimed to investigate sex-dependent differences in a mouse model of caerulein-induced AP. Thirty-six C57BL/6J mice (19 females and 17 males) were treated intraperitoneally with phosphate-buffered saline or caerulein, and sacrificed 12 hours, 2 days, or 7 days after the last injection. Blood was collected for amylase, lipase, and glucose determination. Severity and extent of inflammation, apoptosis, and acinar to ductal metaplasia (ADM) in pancreatic tissue were scored histologically and total macrophages, major histocompatibility complex (MHC)-II+ cells, M2 macrophages, T and B cells, neutrophils, apoptosis, and ADM were marked immunohistochemically and quantified by digital image analysis. Serum amylase had a peak at 12 hours, without differences between the sexes. In females, pancreatitis reached a peak at 12 hours with a fast recovery while, in males, the peak was delayed to day 2 with residual apoptosis still present. Macrophages were the main inflammatory cell population, followed by T cells, B cells and neutrophils, without differences between sexes. In males, CD206+ cells and apoptosis were higher at both days 2 and 7, and cytokeratin-19+ (CK19+) ADM was higher at day 7 compared with females. The results of this study revealed a faster onset and resolution of caerulein-induced AP in female mice compared with male mice, supporting a sex-dependent modulation of acute pancreatitis.

28 September 2024 in Veterinary Research Communications
Verified
Journal Article
Open access
PDF file
APAdina Mihaela Pîrvu
Adina Mihaela Pîrvu
ACAndrea Cappelleri
Andrea Cappelleri
LSLaura Sala
Laura Sala
BBBarbara Banco
Barbara Banco
CGChiara Giudice
Chiara Giudice
Valeria GriecoValeria Grieco
Valeria Grieco
In male cats, as in men, mammary carcinomas are rarely reported. However, like in females, hormonal therapy is a significant risk factor. This study reports the case of an 11-year-old male cat with multiple mammary tumours and a history of long-term medroxyprogesterone acetate therapy for the suppression of sexual behaviour, along with a brief review of the literature. Complete surgical removal of the right mammary chain and the ipsilateral inguinal lymph nodes was performed, and all tissues were submitted for histology. Histological examination revealed the presence of a tumour in the third and fourth mammary glands, consisting of neoplastic cells arranged in various structures, including tubulopapillary and tubular structures, sometimes cystically dilated, and solid areas. The inguinal lymph nodes were also involved. The morphology was consistent with a diagnosis of mammary carcinoma, tubulopapillary type, with nodal metastases. Immunohistochemistry revealed that tumour cells were positive for cytokeratin (clones AE1/AE3), while stromal cells were positive for vimentin (clone V9). The proliferation marker Ki-67, evaluated on both the primary tumour and the nodal metastases, was strongly expressed in the nuclei of neoplastic cells, with a Ki-67 proliferation index of 8.9% and 20% for the primary tumour and the metastases, respectively. This case highlights the importance of considering the possibility of malignant mammary tumours not only in female but also in male cats with a history of long-term hormonal treatment for suppression of sexual behaviour.

4 September 2025 in Preventive Veterinary Medicine
Verified
Journal Article
Open access
MRMatteo Recchia
Matteo Recchia
LSLucia Scuri
Lucia Scuri
CACamilla Allegri
Camilla Allegri
CRClaudia Romeo
Claudia Romeo
FSFederico Scali
Federico Scali
GAGiovanni Loris Alborali
Giovanni Loris Alborali
Accurate classification of lung lesions at necropsy is crucial for guiding the diagnostic process and ensuring effective management of porcine respiratory diseases. Post-mortem inspection of the lungs during slaughter also provides valuable insights into disease occurrence, offering useful feedback on the efficacy of on-farm prevention and control strategies. However, manual assessment protocols may be impaired by high slaughtering speeds and low inter-rater agreement, which limits continuous data collection and hinders comparability. Artificial intelligence, particularly computer vision (CV), may offer a promising alternative. This study aimed to train and test a commercial CV model for segmenting both anatomical structures and lesions in pig lungs. Overall, 1742 lungs were collected at slaughter, examined macroscopically, and photographed laterally. Two veterinarians with expertise in swine pathology manually annotated the acquired images to outline anatomical (i.e., lung, heart, lung lobes), pathological (i.e., bronchopneumonia, fibrinous pleuropneumonia, chronic pleuritis), and artefactual (i.e., parenchymal laceration, bronchoinhalation of blood) classes, forming the reference dataset for model training and testing. Model performance in segmenting these classes varied by confidence threshold, with sensitivity (36-84 %), positive predictive value (62-93 %) and F1 score (52-78 %) indicating imperfect yet improvable performance. Overall, anatomical structure segmentation outperformed lesion detection, likely due to class imbalance in the training dataset and the complexity of pulmonary pathology. Integrating standardized and real-time detection of lung lesions via digital imaging could improve respiratory health surveillance, thereby enhancing the role of abattoirs as strategic epidemiological observatories.

28 January 2026 in Nanomaterials
Verified
Journal Article
Open access
PDF file
SCSimone Canesi
Simone Canesi
LSLaura Sala
Laura Sala
MMMarcella de Maglie
Marcella de Maglie
SRSimona Rodighiero
Simona Rodighiero
SLSilvia Alice Locarno
Silvia Alice Locarno
CRCamilla Recordati
Camilla Recordati
Silver nanoparticles (AgNPs) are extensively employed for their antimicrobial and biomedical properties, yet concerns persist regarding their potential toxicity. While AgNPs can induce oxidative stress, membrane disruption, and DNA damage, in vivo data remain inconsistent. This study investigated whether batch-to-batch variability in nominally identical AgNPs of 10 nm size contributes to divergent in vivo toxicity outcomes. CD-1 (ICR) mice were intravenously injected with a single 10 mg/kg bw dose of spherical, citrate-coated 10 nm AgNPs from three different batches purchased from the same manufacturer. The mice were euthanized 24 h post-exposure for quantitative silver determination by inductively coupled plasma–mass spectrometry (ICP–MS) and histopathological evaluation of liver, spleen, lungs, kidneys, and brain. Autometallography and immunofluorescence were used to assess silver distribution and cellular localization in the hepatobiliary system. All the batches induced hepatobiliary toxicity, characterized by hepatocellular necrosis and gallbladder wall hemorrhage, of differing severity. The most toxic batches contained higher proportions of smaller AgNPs, suggesting that differences in size distribution influence toxicological outcomes. Silver agglomerates were localized within multiple cell types, indicating internalization and cell-specific cytotoxicity. These findings highlight that minor physicochemical variations affect in vivo results, underscoring the importance of nanoparticle characterization to improve reproducibility in nanotoxicological research.

15 September 2026 in Experimental Hematology & Oncology
Verified
Journal Article
Open access
PDF file
MCMichela Chiappa
Michela Chiappa
VVV. Villa
V. Villa
FSFabio Sias
Fabio Sias
CGChiara Grasselli
Chiara Grasselli
LSLaura Sala
Laura Sala
Giovanna DamiaGiovanna Damia
Giovanna Damia
High-grade serous ovarian carcinoma (HGSOC) often shows an initial response to poly (ADP-ribose) polymerase inhibitors (PARPi) such as olaparib, particular